APOBEC3B expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Significance: Somatic mutagenesis is fundamental to the development and evolution of cancers. APOBEC3B (A3B) is a cellular deaminase, which is overexpressed in cancers and believed to be an important cause of cancer-associated mutations. The factors responsible for A3B up-regulation are unknown. Interestingly, a germ-line deletion polymorphism exists, such that a significant proportion of the global population does not express A3B protein. Using large human cancer datasets, we show that A3B expression is strongly associated with cellular proliferation. Furthermore, we identify a pattern of immune activation related to hypermutation in tumors arising in A3B deletion carriers suggesting that these patients could respond differently to immune-directed therapies. These results provide important context for the ongoing study of A3B as a therapeutic target or biomarker.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Individual Comparisons by Ranking Methods
Wilcoxon, F. (1945) · Biometrics Bulletin · doi:10.2307/3001968 · Cited by 15,354
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Use of Ranks in One-Criterion Variance Analysis
Kruskal, W. H., & Wallis, W. A. (1952) · Journal of the American Statistical Association · doi:10.1080/01621459.1952.10483441 · Cited by 13,912 · cited 1×
“To estimate the significance of the association between a continuous variable and a binary variable, we used theWilcoxon rank sum test (23); we used the Kruskal–Wallis test (24) for discrete variables with more than two levels.”
MethodThe Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950 · cited 1×
“For coexpression analysis, in 59 breast cancer cell lines from the Cancer Cell Line Encyclopedia (CCLE) (20) and 16 other solid tumor types from TCGA, we used gene expression data (microarray for CCLE and RNA-seq for TCGA) and the coexpression function implemented on cBioPortal (19).”
MethodMolecular signatures database (MSigDB) 3.0
Liberzon, A., Subramanian, A., Pinchback, R., Thorvaldsdóttir, H., Tamayo, P., & Mesirov, J. P. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr260 · Cited by 7,111 · cited 1×
“Gene sets were defined by all gene ontology (GO) (31) terms extracted from class c5 in MSigDB (32).”
MethodOncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929 · cited 1×
“Antitumor immune responses have been attributed to neoepitopes arising from somatic mutations in cancer cells (41), Fig.”
BackgroundThe genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097 · cited 2×
“We sought to address the biologic and clinical questions raised by these observations using two large clinically annotated breast cancer datasets with gene expression, copy number, and mutational data (1, 18) with the chief aim of resolving the incongruence”
BackgroundMethodMutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Discovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974
Mutational Processes Molding the Genomes of 21 Breast Cancers
Nik-Zainal, S., Alexandrov, L. B., Wedge, D. C., Van Loo, P., Greenman, C. D., Raine, K., Jones, D., Hinton, J., Marshall, J., Stebbings, L. A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.04.024 · Cited by 1,909
Spatial and temporal diversity in genomic instability processes defines lung cancer evolution
de Bruin, E. C., McGranahan, N., Mitter, R., Salm, M., Wedge, D. C., Yates, L., Jamal-Hanjani, M., Shafi, S., Murugaesu, N., Rowan, A. J., et al. (2014) · Science · doi:10.1126/science.1253462 · Cited by 1,117
Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing
Zhang, J., Fujimoto, J., Zhang, J., Wedge, D. C., Song, X., Zhang, J., Seth, S., Chow, C.-W., Cao, Y., Gumbs, C., et al. (2014) · Science · doi:10.1126/science.1256930 · Cited by 965
Wang, C., Gong, B., Bushel, P. R., Thierry-Mieg, J., Thierry-Mieg, D., Xu, J., Fang, H., Hong, H., Shen, J., Su, Z., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.3001 · Cited by 512 · cited 1×
“Results from TCGA are shown in the figures for coexpression and gene signature analyses, because the RNA-seq data in this dataset provide a more quantitative measurement (34).”
MethodA new measure of prognostic separation in survival data
Royston, P., & Sauerbrei, W. (2004) · Statistics in Medicine · doi:10.1002/sim.1621 · Cited by 450 · cited 1×
“In particular, we used the D index (26) as a robust, unit-free estimate of the hazard ratio (HR).”
MethodNik-Zainal, S., Wedge, D. C., Alexandrov, L. B., Petljak, M., Butler, A. P., Bolli, N., Davies, H. R., Knappskog, S., Martin, S., Papaemmanuil, E., et al. (2014) · Nature Genetics · doi:10.1038/ng.2955 · Cited by 277 · cited 6×
“Because hypermutation is likely a continuum but was binarized in these analyses (17), some or all of the residual immuneassociated patterns in A3B tumors may also be attributable to degrees of hypermutation.”
BackgroundMethodInfluential
Cited by
Current state of immunotherapy for glioblastoma
Lim, M., Xia, Y., Bettegowda, C., & Weller, M. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0003-5 · Cited by 1,365
APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and Heterogeneity
Swanton, C., McGranahan, N., Starrett, G. J., & Harris, R. S. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0344 · Cited by 488
Chan, K., Roberts, S. A., Klimczak, L. J., Sterling, J. F., Saini, N., Malc, E. P., Kim, J., Kwiatkowski, D. J., Fargo, D. C., Mieczkowski, P. A., et al. (2015) · Nature Genetics · doi:10.1038/ng.3378 · Cited by 414
Middlebrooks, C. D., Banday, A. R., Matsuda, K., Udquim, K.-I., Onabajo, O. O., Paquin, A., Figueroa, J. D., Zhu, B., Koutros, S., Kubo, M., et al. (2016) · Nature Genetics · doi:10.1038/ng.3670 · Cited by 185
APOBEC Enzymes as Targets for Virus and Cancer Therapy
Olson, M. E., Harris, R. S., & Harki, D. A. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.10.007 · Cited by 164
Metadata
- Authors
- Cescon, D. W., Haibe-Kains, B., & Mak, T. W.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2015-02-17
- Volume
- 112
- Issue
- 9
- Pages
- 2841-2846
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2132767411
- Cited by
- 134
- References
- 18
- FWCI
- 5.99
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.